Cargando…

MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer

Depletion of BRCA1 protein in mouse mammary glands results in defects in lactational development and increased susceptibility to mammary cancer. Extensive work has focussed on the role of BRCA1 in the normal breast and in the development of breast cancer, the cell of origin for BRCA1 tumours and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Milevskiy, Michael J.G., Sandhu, Gurveen K., Wronski, Anna, Korbie, Darren, Brewster, Brooke L., Shewan, Annette, Edwards, Stacey L., French, Juliet D., Brown, Melissa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173367/
https://www.ncbi.nlm.nih.gov/pubmed/30323900
http://dx.doi.org/10.18632/oncotarget.26094
_version_ 1783361112971935744
author Milevskiy, Michael J.G.
Sandhu, Gurveen K.
Wronski, Anna
Korbie, Darren
Brewster, Brooke L.
Shewan, Annette
Edwards, Stacey L.
French, Juliet D.
Brown, Melissa A.
author_facet Milevskiy, Michael J.G.
Sandhu, Gurveen K.
Wronski, Anna
Korbie, Darren
Brewster, Brooke L.
Shewan, Annette
Edwards, Stacey L.
French, Juliet D.
Brown, Melissa A.
author_sort Milevskiy, Michael J.G.
collection PubMed
description Depletion of BRCA1 protein in mouse mammary glands results in defects in lactational development and increased susceptibility to mammary cancer. Extensive work has focussed on the role of BRCA1 in the normal breast and in the development of breast cancer, the cell of origin for BRCA1 tumours and the protein-coding genes altered in BRCA1 deficient cells. However, the role of non-coding RNAs in BRCA1-deficient cells is poorly understood. To evaluate miRNA expression in BRCA1 deficient mammary cells, RNA sequencing was performed on the mammary glands of Brca1 knockout mice. We identified 140 differentially expressed miRNAs, 9 of which were also differentially expressed in human BRCA1 breast tumours or familial non-BRCA1 patients and during normal gland development. We show that BRCA1 binds to putative cis-elements in promoter regions of the miRNAs with the potential to regulate their expression, and that four miRNAs (miR-29b-1-5p, miR-664, miR-16-2 and miR-744) significantly stratified the overall survival of basal-like tumours. Importantly the prognostic value of miR-29b-1-5p was higher in significance than several commonly used clinical biomarkers. These results emphasise the role of Brca1 in modulating expression of miRNAs and highlights the potential for BRCA1 regulated miRNAs to be informative biomarkers associated with BRCA1 loss and survival in breast cancer.
format Online
Article
Text
id pubmed-6173367
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-61733672018-10-15 MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer Milevskiy, Michael J.G. Sandhu, Gurveen K. Wronski, Anna Korbie, Darren Brewster, Brooke L. Shewan, Annette Edwards, Stacey L. French, Juliet D. Brown, Melissa A. Oncotarget Research Paper Depletion of BRCA1 protein in mouse mammary glands results in defects in lactational development and increased susceptibility to mammary cancer. Extensive work has focussed on the role of BRCA1 in the normal breast and in the development of breast cancer, the cell of origin for BRCA1 tumours and the protein-coding genes altered in BRCA1 deficient cells. However, the role of non-coding RNAs in BRCA1-deficient cells is poorly understood. To evaluate miRNA expression in BRCA1 deficient mammary cells, RNA sequencing was performed on the mammary glands of Brca1 knockout mice. We identified 140 differentially expressed miRNAs, 9 of which were also differentially expressed in human BRCA1 breast tumours or familial non-BRCA1 patients and during normal gland development. We show that BRCA1 binds to putative cis-elements in promoter regions of the miRNAs with the potential to regulate their expression, and that four miRNAs (miR-29b-1-5p, miR-664, miR-16-2 and miR-744) significantly stratified the overall survival of basal-like tumours. Importantly the prognostic value of miR-29b-1-5p was higher in significance than several commonly used clinical biomarkers. These results emphasise the role of Brca1 in modulating expression of miRNAs and highlights the potential for BRCA1 regulated miRNAs to be informative biomarkers associated with BRCA1 loss and survival in breast cancer. Impact Journals LLC 2018-09-11 /pmc/articles/PMC6173367/ /pubmed/30323900 http://dx.doi.org/10.18632/oncotarget.26094 Text en Copyright: © 2018 Milevskiy et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Milevskiy, Michael J.G.
Sandhu, Gurveen K.
Wronski, Anna
Korbie, Darren
Brewster, Brooke L.
Shewan, Annette
Edwards, Stacey L.
French, Juliet D.
Brown, Melissa A.
MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer
title MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer
title_full MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer
title_fullStr MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer
title_full_unstemmed MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer
title_short MiR-29b-1-5p is altered in BRCA1 mutant tumours and is a biomarker in basal-like breast cancer
title_sort mir-29b-1-5p is altered in brca1 mutant tumours and is a biomarker in basal-like breast cancer
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173367/
https://www.ncbi.nlm.nih.gov/pubmed/30323900
http://dx.doi.org/10.18632/oncotarget.26094
work_keys_str_mv AT milevskiymichaeljg mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer
AT sandhugurveenk mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer
AT wronskianna mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer
AT korbiedarren mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer
AT brewsterbrookel mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer
AT shewanannette mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer
AT edwardsstaceyl mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer
AT frenchjulietd mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer
AT brownmelissaa mir29b15pisalteredinbrca1mutanttumoursandisabiomarkerinbasallikebreastcancer